Pricing
  1. JP-listed companies
  2. Kringle Pharma,Inc.
  3. Financials
  4. Net income

Kringle Pharma,Inc. (4884)

Market cap
¥2.7B
P/E ratio
-2.3x
Kringel Pharma develops treatments for rare diseases like spinal cord injury and ALS using recombinant human HGF protein technology for medical institutions and pharma partners.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Sep 30, 2025-916+21.13%
Sep 30, 2024-756-11.44%
Sep 30, 2023-854+157.41%
Sep 30, 2022-332+10.18%
Sep 30, 2021-301+155.59%
Sep 30, 2020-118-60.99%
Sep 30, 2019-302+367.90%
Sep 30, 2018-65-36.77%
Sep 30, 2017-102-201.89%
Sep 30, 2016100-150.02%
Sep 30, 2015-200

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat